-
1
-
-
13344277357
-
Early neonatal death in mice homozygous for a null allele of the insulin receptor gene
-
Accili, D., Drago, J., Lee, E.J., Johnson, M.D., Cool, M.H., Salvatore, P., Asico, L.D., Jose, P.A., Taylor, S.I. & Westphal, H. (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12, 106-109.
-
(1996)
Nat. Genet.
, vol.12
, pp. 106-109
-
-
Accili, D.1
Drago, J.2
Lee, E.J.3
Johnson, M.D.4
Cool, M.H.5
Salvatore, P.6
Asico, L.D.7
Jose, P.A.8
Taylor, S.I.9
Westphal, H.10
-
2
-
-
77955530763
-
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
-
Ahmed, A.A., Lu, Z., Jennings, N.B., et al. (2010) SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18, 109-121.
-
(2010)
Cancer Cell
, vol.18
, pp. 109-121
-
-
Ahmed, A.A.1
Lu, Z.2
Jennings, N.B.3
-
3
-
-
20344362911
-
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
-
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C.G., Schwartz, B. & Piccart, M. (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861.
-
(2005)
Br. J. Cancer
, vol.92
, pp. 1855-1861
-
-
Awada, A.1
Hendlisz, A.2
Gil, T.3
Bartholomeus, S.4
Mano, M.5
de Valeriola, D.6
Strumberg, D.7
Brendel, E.8
Haase, C.G.9
Schwartz, B.10
Piccart, M.11
-
4
-
-
0037392942
-
The specificities of protein kinase inhibitors: an update
-
Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. (2003) The specificities of protein kinase inhibitors: an update. Biochem J. 371, 199-204.
-
(2003)
Biochem J.
, vol.371
, pp. 199-204
-
-
Bain, J.1
McLauchlan, H.2
Elliott, M.3
Cohen, P.4
-
5
-
-
36549040859
-
The selectivity of protein kinase inhibitors: a further update
-
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H., Klevernic, I., Arthur, J.S., Alessi, D.R. & Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J. 408, 297-315.
-
(2007)
Biochem J.
, vol.408
, pp. 297-315
-
-
Bain, J.1
Plater, L.2
Elliott, M.3
Shpiro, N.4
Hastie, C.J.5
McLauchlan, H.6
Klevernic, I.7
Arthur, J.S.8
Alessi, D.R.9
Cohen, P.10
-
6
-
-
0036857484
-
A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer
-
Bankston, D., Dumas, J., Natero, R., Riedl, B., Monahan, M.-K. & Sibley, R. (2002) A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer. Org. Proc. Res. Dev. 6, 777-781.
-
(2002)
Org. Proc. Res. Dev.
, vol.6
, pp. 777-781
-
-
Bankston, D.1
Dumas, J.2
Natero, R.3
Riedl, B.4
Monahan, M.-K.5
Sibley, R.6
-
7
-
-
34948875686
-
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
-
Bantscheff, M., Eberhard, D., Abraham, Y., et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044.
-
(2007)
Nat. Biotechnol.
, vol.25
, pp. 1035-1044
-
-
Bantscheff, M.1
Eberhard, D.2
Abraham, Y.3
-
8
-
-
74049088133
-
Pazopanib
-
Bukowski, R.M., Yasothan, U. & Kirkpatrick, P. (2010) Pazopanib. Nat. Rev. Drug. Discov. 9, 17-18.
-
(2010)
Nat. Rev. Drug. Discov.
, vol.9
, pp. 17-18
-
-
Bukowski, R.M.1
Yasothan, U.2
Kirkpatrick, P.3
-
9
-
-
70350743116
-
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies
-
Burris, H.A. III, Taylor, C.W., Jones, S.F., Koch, K.M., Versola, M.J., Arya, N., Fleming, R.A., Smith, D.A., Pandite, L., Spector, N. & Wilding, G. (2009) A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin. Cancer Res. 15, 6702-6708.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 6702-6708
-
-
Burris III, H.A.1
Taylor, C.W.2
Jones, S.F.3
Koch, K.M.4
Versola, M.J.5
Arya, N.6
Fleming, R.A.7
Smith, D.A.8
Pandite, L.9
Spector, N.10
Wilding, G.11
-
10
-
-
76649094893
-
Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress
-
Chintalgattu, V., Ai, D., Langley, R.R., et al. (2010) Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472-484.
-
(2010)
J. Clin. Invest.
, vol.120
, pp. 472-484
-
-
Chintalgattu, V.1
Ai, D.2
Langley, R.R.3
-
11
-
-
36849023013
-
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
-
Chu, T.F., Rupnick, M.A., Kerkela, R., et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
-
(2007)
Lancet
, vol.370
, pp. 2011-2019
-
-
Chu, T.F.1
Rupnick, M.A.2
Kerkela, R.3
-
12
-
-
0036094117
-
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
-
Cohen, M.H., Williams, G., Johnson, J.R., Duan, J., Gobburu, J., Rahman, A., Benson, K., Leighton, J., Kim, S.K., Wood, R., Rothmann, M., Chen, G., U, K.M., Staten, A.M. & Pazdur, R. (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935-942.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 935-942
-
-
Cohen, M.H.1
Williams, G.2
Johnson, J.R.3
Duan, J.4
Gobburu, J.5
Rahman, A.6
Benson, K.7
Leighton, J.8
Kim, S.K.9
Wood, R.10
Rothmann, M.11
Chen, G.U.K.M.12
Staten, A.M.13
Pazdur, R.14
-
13
-
-
0043210670
-
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets
-
Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G. & Pazdur, R. (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8, 303-306.
-
(2003)
Oncologist
, vol.8
, pp. 303-306
-
-
Cohen, M.H.1
Williams, G.A.2
Sridhara, R.3
Chen, G.4
Pazdur, R.5
-
14
-
-
0034797512
-
The role of protein phosphorylation in human health and disease The Sir Hans Krebs Medal Lecture
-
Cohen, P. (2001) The role of protein phosphorylation in human health and disease The Sir Hans Krebs Medal Lecture. Eur. J. Biochem. 268, 5001-5010.
-
(2001)
Eur. J. Biochem.
, vol.268
, pp. 5001-5010
-
-
Cohen, P.1
-
15
-
-
0036527429
-
Protein kinases-the major drug targets of the twenty-first century?
-
Cohen, P. (2002) Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug. Discov. 1, 309-315.
-
(2002)
Nat. Rev. Drug. Discov.
, vol.1
, pp. 309-315
-
-
Cohen, P.1
-
16
-
-
0036795899
-
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors
-
Dagher, R., Cohen, M., Williams, G., Rothmann, M., Gobburu, J., Robbie, G., Rahman, A., Chen, G., Staten, A., Griebel, D. & Pazdur, R. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8, 3034-3038.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 3034-3038
-
-
Dagher, R.1
Cohen, M.2
Williams, G.3
Rothmann, M.4
Gobburu, J.5
Robbie, G.6
Rahman, A.7
Chen, G.8
Staten, A.9
Griebel, D.10
Pazdur, R.11
-
17
-
-
0034306450
-
Specificity and mechanism of action of some commonly used protein kinase inhibitors
-
Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105.
-
(2000)
Biochem. J.
, vol.351
, pp. 95-105
-
-
Davies, S.P.1
Reddy, H.2
Caivano, M.3
Cohen, P.4
-
18
-
-
70349673597
-
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
-
Demetri, G.D., Lo Russo, P., MacPherson, I.R., Wang, D., Morgan, J.A., Brunton, V.G., Paliwal, P., Agrawal, S., Voi, M. & Evans, T.R. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res. 15, 6232-6240.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 6232-6240
-
-
Demetri, G.D.1
Lo Russo, P.2
MacPherson, I.R.3
Wang, D.4
Morgan, J.A.5
Brunton, V.G.6
Paliwal, P.7
Agrawal, S.8
Voi, M.9
Evans, T.R.10
-
19
-
-
78650334298
-
Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo
-
Ding, P., Huang, J., Battiprolu, P.K., Hill, J.A., Kamm, K.E. & Stull, J.T. (2010) Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. J. Biol. Chem. 285, 40819-40829.
-
(2010)
J. Biol. Chem.
, vol.285
, pp. 40819-40829
-
-
Ding, P.1
Huang, J.2
Battiprolu, P.K.3
Hill, J.A.4
Kamm, K.E.5
Stull, J.T.6
-
20
-
-
19744365702
-
A small molecule-kinase interaction map for clinical kinase inhibitors
-
Fabian, M.A., Biggs, W.H. III, Treiber, D.K., et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336.
-
(2005)
Nat. Biotechnol.
, vol.23
, pp. 329-336
-
-
Fabian, M.A.1
Biggs III, W.H.2
Treiber, D.K.3
-
21
-
-
38049155899
-
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
-
Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Muller, S., Bullock, A.N., Schwaller, J., Sundstrom, M. & Knapp, S. (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl Acad. Sci. USA 104, 20523-20528.
-
(2007)
Proc. Natl Acad. Sci. USA
, vol.104
, pp. 20523-20528
-
-
Fedorov, O.1
Marsden, B.2
Pogacic, V.3
Rellos, P.4
Muller, S.5
Bullock, A.N.6
Schwaller, J.7
Sundstrom, M.8
Knapp, S.9
-
22
-
-
79551610758
-
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
-
Force, T. & Kolaja, K.L. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-126.
-
(2011)
Nat. Rev. Drug Discov.
, vol.10
, pp. 111-126
-
-
Force, T.1
Kolaja, K.L.2
-
23
-
-
60849113175
-
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
-
Gajiwala, K.S., Wu, J.C., Christensen, J., et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl Acad. Sci. USA 106, 1542-1547.
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 1542-1547
-
-
Gajiwala, K.S.1
Wu, J.C.2
Christensen, J.3
-
24
-
-
33947423448
-
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
-
Goodman, V.L., Rock, E.P., Dagher, R., et al. (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367-1373.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1367-1373
-
-
Goodman, V.L.1
Rock, E.P.2
Dagher, R.3
-
25
-
-
77950042300
-
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
-
Hasinoff, B.B. (2010) The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244, 190-195.
-
(2010)
Toxicol. Appl. Pharmacol.
, vol.244
, pp. 190-195
-
-
Hasinoff, B.B.1
-
26
-
-
0037106377
-
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
-
Herbst, R.S., Maddox, A.M., Rothenberg, M.L., Small, E.J., Rubin, E.H., Baselga, J., Rojo, F., Hong, W.K., Swaisland, H., Averbuch, S.D., Ochs, J. & LoRusso, P.M. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20, 3815-3825.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 3815-3825
-
-
Herbst, R.S.1
Maddox, A.M.2
Rothenberg, M.L.3
Small, E.J.4
Rubin, E.H.5
Baselga, J.6
Rojo, F.7
Hong, W.K.8
Swaisland, H.9
Averbuch, S.D.10
Ochs, J.11
LoRusso, P.M.12
-
27
-
-
65249087328
-
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
-
Houk, B.E., Bello, C.L., Kang, D. & Amantea, M. (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15, 2497-2506.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 2497-2506
-
-
Houk, B.E.1
Bello, C.L.2
Kang, D.3
Amantea, M.4
-
28
-
-
79955752557
-
Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques
-
Hurtado, B., Munoz, X., Recarte-Pelz, P., Garcia, N., Luque, A., Krupinski, J., Sala, N. & Garcia de Frutos, P. (2011) Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques. Thromb. Haemost. 105, 873-882.
-
(2011)
Thromb. Haemost.
, vol.105
, pp. 873-882
-
-
Hurtado, B.1
Munoz, X.2
Recarte-Pelz, P.3
Garcia, N.4
Luque, A.5
Krupinski, J.6
Sala, N.7
Garcia de Frutos, P.8
-
29
-
-
67449164582
-
Phase I trial of pazopanib in patients with advanced cancer
-
Hurwitz, H.I., Dowlati, A., Saini, S., Savage, S., Suttle, A.B., Gibson, D.M., Hodge, J.P., Merkle, E.M. & Pandite, L. (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220-4227.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 4220-4227
-
-
Hurwitz, H.I.1
Dowlati, A.2
Saini, S.3
Savage, S.4
Suttle, A.B.5
Gibson, D.M.6
Hodge, J.P.7
Merkle, E.M.8
Pandite, L.9
-
30
-
-
70349449239
-
Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators
-
Imamura, H., Nhat, K.P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai, T. & Noji, H. (2009) Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc. Natl Acad. Sci. USA 106, 15651-15656.
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, pp. 15651-15656
-
-
Imamura, H.1
Nhat, K.P.2
Togawa, H.3
Saito, K.4
Iino, R.5
Kato-Yamada, Y.6
Nagai, T.7
Noji, H.8
-
31
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
Kantarjian, H., Giles, F., Wunderle, L., et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551.
-
(2006)
N. Engl. J. Med.
, vol.354
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
-
32
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
Karaman, M.W., Herrgard, S., Treiber, D.K., et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132.
-
(2008)
Nat. Biotechnol.
, vol.26
, pp. 127-132
-
-
Karaman, M.W.1
Herrgard, S.2
Treiber, D.K.3
-
33
-
-
41349085814
-
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
-
Khorashad, J.S., Milojkovic, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A.G., De Melo, V., Babb, A., de Lavallade, H., Olavarria, E., Marin, D., Goldman, J.M., Apperley, J.F. & Kaeda, J.S. (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111, 2378-2381.
-
(2008)
Blood
, vol.111
, pp. 2378-2381
-
-
Khorashad, J.S.1
Milojkovic, D.2
Mehta, P.3
Anand, M.4
Ghorashian, S.5
Reid, A.G.6
De Melo, V.7
Babb, A.8
de Lavallade, H.9
Olavarria, E.10
Marin, D.11
Goldman, J.M.12
Apperley, J.F.13
Kaeda, J.S.14
-
34
-
-
39549099724
-
Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase
-
Kinoshita, T., Miyano, N., Nakai, R., Yokota, K., Ishiguro, H. & Tada, T. (2008) Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase. Protein Expr. Purif. 58, 318-324.
-
(2008)
Protein Expr. Purif.
, vol.58
, pp. 318-324
-
-
Kinoshita, T.1
Miyano, N.2
Nakai, R.3
Yokota, K.4
Ishiguro, H.5
Tada, T.6
-
35
-
-
84855221082
-
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase
-
Kitagawa, D., Gouda, M., Kirii, Y., Sugiyama, N., Ishihama, Y., Fujii, I., Narumi, Y., Akita, K. & Yokota, K. (2012) Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. J. Biochem. 151, 47-55.
-
(2012)
J. Biochem.
, vol.151
, pp. 47-55
-
-
Kitagawa, D.1
Gouda, M.2
Kirii, Y.3
Sugiyama, N.4
Ishihama, Y.5
Fujii, I.6
Narumi, Y.7
Akita, K.8
Yokota, K.9
-
36
-
-
24944497371
-
Features of selective kinase inhibitors
-
Knight, Z.A. & Shokat, K.M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
-
(2005)
Chem. Biol.
, vol.12
, pp. 621-637
-
-
Knight, Z.A.1
Shokat, K.M.2
-
37
-
-
41449111037
-
c-kit is required for cardiomyocyte terminal differentiation
-
Li, M., Naqvi, N., Yahiro, E., Liu, K., Powell, P.C., Bradley, W.E., Martin, D.I., Graham, R.M., Dell'Italia, L.J. & Husain, A. (2008) c-kit is required for cardiomyocyte terminal differentiation. Circ. Res. 102, 677-685.
-
(2008)
Circ. Res.
, vol.102
, pp. 677-685
-
-
Li, M.1
Naqvi, N.2
Yahiro, E.3
Liu, K.4
Powell, P.C.5
Bradley, W.E.6
Martin, D.I.7
Graham, R.M.8
Dell'Italia, L.J.9
Husain, A.10
-
38
-
-
19944428353
-
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
Lombardo, L.J., Lee, F.Y., Chen, P., et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
-
(2004)
J. Med. Chem.
, vol.47
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
-
39
-
-
75349094716
-
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
-
Manley, P.W., Drueckes, P., Fendrich, G., Furet, P., Liebetanz, J., Martiny-Baron, G., Mestan, J., Trappe, J., Wartmann, M. & Fabbro, D. (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta 1804, 445-453.
-
(2010)
Biochim. Biophys. Acta
, vol.1804
, pp. 445-453
-
-
Manley, P.W.1
Drueckes, P.2
Fendrich, G.3
Furet, P.4
Liebetanz, J.5
Martiny-Baron, G.6
Mestan, J.7
Trappe, J.8
Wartmann, M.9
Fabbro, D.10
-
40
-
-
0037032835
-
The protein kinase complement of the human genome
-
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
-
(2002)
Science
, vol.298
, pp. 1912-1934
-
-
Manning, G.1
Whyte, D.B.2
Martinez, R.3
Hunter, T.4
Sudarsanam, S.5
-
42
-
-
33846821872
-
Targeted therapy for metastatic renal cell carcinoma
-
Motzer, R.J. & Bukowski, R.M. (2006) Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 5601-5608
-
-
Motzer, R.J.1
Bukowski, R.M.2
-
43
-
-
34548744667
-
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
-
Piccaluga, P.P., Paolini, S. & Martinelli, G. (2007) Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110, 1178-1186.
-
(2007)
Cancer
, vol.110
, pp. 1178-1186
-
-
Piccaluga, P.P.1
Paolini, S.2
Martinelli, G.3
-
44
-
-
55249102194
-
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases
-
Quintas-Cardama, A. & Cortes, J. (2008) Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 4, 611-621.
-
(2008)
Future Oncol.
, vol.4
, pp. 611-621
-
-
Quintas-Cardama, A.1
Cortes, J.2
-
45
-
-
33846440150
-
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
-
Rock, E.P., Goodman, V., Jiang, J.X., Mahjoob, K., Verbois, S.L., Morse, D., Dagher, R., Justice, R. & Pazdur, R. (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12, 107-113.
-
(2007)
Oncologist
, vol.12
, pp. 107-113
-
-
Rock, E.P.1
Goodman, V.2
Jiang, J.X.3
Mahjoob, K.4
Verbois, S.L.5
Morse, D.6
Dagher, R.7
Justice, R.8
Pazdur, R.9
-
46
-
-
84901290217
-
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2
-
Ryan, Q., Ibrahim, A., Cohen, M.H., Johnson, J., Ko, C.W., Sridhara, R., Justice, R. & Pazdur, R. (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13, 1114-1119.
-
(2008)
Oncologist
, vol.13
, pp. 1114-1119
-
-
Ryan, Q.1
Ibrahim, A.2
Cohen, M.H.3
Johnson, J.4
Ko, C.W.5
Sridhara, R.6
Justice, R.7
Pazdur, R.8
-
47
-
-
0034665713
-
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
-
Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. & Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942.
-
(2000)
Science
, vol.289
, pp. 1938-1942
-
-
Schindler, T.1
Bornmann, W.2
Pellicena, P.3
Miller, W.T.4
Clarkson, B.5
Kuriyan, J.6
-
48
-
-
0037468875
-
Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
-
Sun, L., Liang, C., Shirazian, S., et al. (2003) Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2, 4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116-1119.
-
(2003)
J. Med. Chem.
, vol.46
, pp. 1116-1119
-
-
Sun, L.1
Liang, C.2
Shirazian, S.3
-
49
-
-
4143149763
-
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
-
Tan, A.R., Yang, X., Hewitt, S.M., et al. (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 22, 3080-3090.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 3080-3090
-
-
Tan, A.R.1
Yang, X.2
Hewitt, S.M.3
-
50
-
-
49549105363
-
Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis
-
Thirunavukkarasu, M., Addya, S., Juhasz, B., Pant, R., Zhan, L., Surrey, S., Maulik, G., Menon, V.P. & Maulik, N. (2008) Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J. Cell Mol. Med. 12, 1284-1302.
-
(2008)
J. Cell Mol. Med.
, vol.12
, pp. 1284-1302
-
-
Thirunavukkarasu, M.1
Addya, S.2
Juhasz, B.3
Pant, R.4
Zhan, L.5
Surrey, S.6
Maulik, G.7
Menon, V.P.8
Maulik, N.9
-
51
-
-
33847281812
-
The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain
-
Walter, M., Lucet, I.S., Patel, O., Broughton, S.E., Bamert, R., Williams, N.K., Fantino, E., Wilks, A.F. & Rossjohn, J. (2007) The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J. Mol. Biol. 367, 839-847.
-
(2007)
J. Mol. Biol.
, vol.367
, pp. 839-847
-
-
Walter, M.1
Lucet, I.S.2
Patel, O.3
Broughton, S.E.4
Bamert, R.5
Williams, N.K.6
Fantino, E.7
Wilks, A.F.8
Rossjohn, J.9
-
52
-
-
33745114173
-
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
-
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A. & Griffin, J.D. (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 94, 1765-1769.
-
(2006)
Br. J. Cancer
, vol.94
, pp. 1765-1769
-
-
Weisberg, E.1
Manley, P.2
Mestan, J.3
Cowan-Jacob, S.4
Ray, A.5
Griffin, J.D.6
-
53
-
-
35348868577
-
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
-
White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M.F., Lynch, K., To, L.B. & Hughes, T. (2007) Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J. Clin. Oncol. 25, 4445-4451.
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 4445-4451
-
-
White, D.1
Saunders, V.2
Grigg, A.3
Arthur, C.4
Filshie, R.5
Leahy, M.F.6
Lynch, K.7
To, L.B.8
Hughes, T.9
-
54
-
-
43649107281
-
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
-
Widmer, N., Decosterd, L.A., Leyvraz, S., Duchosal, M.A., Rosselet, A., Debiec-Rychter, M., Csajka, C., Biollaz, J. & Buclin, T. (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br. J. Cancer 98, 1633-1640.
-
(2008)
Br. J. Cancer
, vol.98
, pp. 1633-1640
-
-
Widmer, N.1
Decosterd, L.A.2
Leyvraz, S.3
Duchosal, M.A.4
Rosselet, A.5
Debiec-Rychter, M.6
Csajka, C.7
Biollaz, J.8
Buclin, T.9
-
55
-
-
33749238553
-
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
-
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R. & Kelley, S. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835-844.
-
(2006)
Nat. Rev. Drug Discov.
, vol.5
, pp. 835-844
-
-
Wilhelm, S.1
Carter, C.2
Lynch, M.3
Lowinger, T.4
Dumas, J.5
Smith, R.A.6
Schwartz, B.7
Simantov, R.8
Kelley, S.9
-
56
-
-
55949114398
-
AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice
-
Zhang, P., Hu, X., Xu, X., Fassett, J., Zhu, G., Viollet, B., Xu, W., Wiczer, B., Bernlohr, D.A., Bache, R.J. & Chen, Y. (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52, 918-924.
-
(2008)
Hypertension
, vol.52
, pp. 918-924
-
-
Zhang, P.1
Hu, X.2
Xu, X.3
Fassett, J.4
Zhu, G.5
Viollet, B.6
Xu, W.7
Wiczer, B.8
Bernlohr, D.A.9
Bache, R.J.10
Chen, Y.11
-
57
-
-
68449098174
-
Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors
-
Zsila, F., Fitos, I., Bencze, G., Keri, G. & Orfi, L. (2009) Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr. Med. Chem. 16, 1964-1977.
-
(2009)
Curr. Med. Chem.
, vol.16
, pp. 1964-1977
-
-
Zsila, F.1
Fitos, I.2
Bencze, G.3
Keri, G.4
Orfi, L.5
|